Practicing evidence-based psychiatry: 1. Applying a study's findings: The threats to validity approach

Asian Journal of Psychiatry

Volumn 3, Issue 1, 2010, Pages 35-40

  Rankupalli, Babu ^a   Tandon, Rajiv ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic treatment; CATIE; Clinical trial; Evidence based medicine; Validity

Indexed keywords

NEUROLEPTIC AGENT;

AMBIGUITY; ARTICLE; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CONSTRUCT VALIDITY; EVIDENCE BASED MEDICINE; EXTERNAL VALIDITY; HUMAN; INTERNAL VALIDITY; METHODOLOGY; PRIORITY JOURNAL; PSYCHIATRY; SCHIZOPHRENIA; THREAT; TREATMENT OUTCOME; VIGNETTE;

EID: 77949916872     PISSN: 18762018     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajp.2010.01.002     Document Type: Article

References (25)

1. Carpenter W.T., and Buchanan R.W. Lessons to take home from CATIE. Psychiatr. Serv. 59 (2008) 523-525
2. Chen H., and Tandon R. First- and second-generation antipsychotics and the concept of "atypicality": implications for clinical practice. Psychopharm Rev. 44 (2009) 81-88
3. Citrome L., and Stroup T.S. Schizophrenia, clinical antipsychotic trials of intervention effectiveness (CATIE), and number needed to treat: how can CATIE inform clinicians?. Int. J. Clin. Pract. 60 (2006) 933-940
4. Cook T.D., and Campbell D.T. Quasi-Experimentation: Design and Analysis Issues for Field Settings (1979), Rand-McNally, Chicago
5. Essock S.M., Covell N.H., Davis S.M., et al. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry 163 (2006) 2090-2095
6. Heres S., Davis J., Maino K., et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry 163 (2006) 185-194
7. Hill A.B. The environment and disease: association or causation. Proc. Roy. Coll. Med. 58 (1962) 295-300
8. Ioannidis J.P. Some main problems eroding the credibility and relevance of randomized trials. Bull. NYU Hosp. Jt. Dis. 66 (2008) 135-139
9. Karagianis J., Rosenbluth M., Tohen M., et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr. Med. Res. Opin. 23 (2007) 2551-2557
10. Kraemer H.C., and Robinson T.N. Are certain multi-center randomized clinical trials structures misleading clinical and policy decisions?. Contr. Clin. Trials 26 (2005) 518-529
11. Kraemer H.C., Glick I.D., and Klein D.F. Clinical trials design lessons from the CATIE study. Am. J. Psychiatry 166 (2009) 1222-1228
12. Lewis S., and Lieberman J. CATIE CUtLASS: can we handle the truth?. Br. J. Psychiatry 192 (2008) 161-163
13. Lieberman J.A., Stroup S.T., McEvoy J.P., et al. Effectiveness of antipsychotics in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
14. Meltzer H.Y., and Bobo W.V. Interpreting the efficacy findings in the CATIE study: what the clinician should know. CNS Spectrums 11 Suppl. 7 (2006) 14-24
15. Miller D.D., Caroff S.N., Davis S.M., et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br. J. Psychiatry 193 (2008) 279-288
16. Moller H.-J. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Eur. Arch. Psychiatry Clin. Neurosci. 255 (2005) 371-372
17. Mulder R.T., Frampton C., Joyce P.R., and Porter R. Randomized controlled trials in psychiatry. Part II. Their relationship to clinical practice. Aust. N. Z. J. Psychiatry 37 (2003) 265-269
18. Osser D.N. Cleaning up evidence-based psychopharmacology. Psychopharm Rev. 43 (2008) 19-26
19. Owens D.G.C. What CATIE did: some thoughts deep and wide. Psychiatr. Ser. 59 (2008) 530-533
20. Sackett D.L., Straus S.E., Richardon W.S., et al. Evidence-Based Medicine: How to Practice and Teach EBM. 2nd edition (2000), Churchill Livingstone, Edinburgh
21. Shadish W.R., Cook T.D., and Campbell D.T. Experimental and Quasi-Experimental Designs for Generalized Causal Inference (2002), Houghton Mifflin Co., Boston
22. Slack M.K., and Draugalis J.R. Establishing the internal and external validity of experimental studies. Am. J. Health Syst. Pharm. 58 (2001) 2173-2181
23. Tandon R., Targum S.D., Nasrallah H.A., and Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J. Psychiatr. Pract. 12 (2006) 348-363
24. Tandon R., Carpenter W.T., and Davis J.M. First- and second-generation antipsychotics: learning from CATIE and CUtLASS. Arch. Gen. Psychiatry 64 (2007) 977-979
25. Tandon R., Belmaker R.H., Gattaz W.F., et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 100 (2008) 20-38